Therefore, B7-H3 was referred to as a pan-cancer antigen, and various preclinical studies and clinical trials have been and are being conducted to exploit B7-H3 as a tumor specific therapeutic target, for example for bispecific antibodies (anti-CD3 x anti-B7-H3) linking immune cells to tumor cells, or for CAR-T cells (Yang et al. 2020; Kontos et al. 2021; Zhou and Jin 2021). This evidence concerns the gene CD276 and neoplasm.